/ EN



About MingMed

MingMed Biotechnology Co., Ltd. is an innovative company focusing on the development of first-in-class pharmaceutical products. The company features world class research scientists and groundbreaking discovery platforms. The core R & D team includes five national experts and several global industry leaders. The product pipeline covers ophthalmology, small molecule immuno oncology, gene editing- based immunotherapy, medical aesthetics and pet medicine. The company have more than ten ongoing projects, most of which are groundbreaking first-in-class products with clinical proof-of-concept data.



With the seminal discovery in dry AMD and dry eye pathogenesis, we aim to translate the scientific breakthrough into ophthalmic products that meet the unmet clinical demand. The goal is to launch several Traditional Chinese Medicine products in China and to advance small molecule projects to clinical stage worldwide. In ophthalmology field, we strive to become the leader in China and a competitor of the world.


Small molecule immune oncology

Focusing on a novel immune oncology target that are highly pursued by global pharmaceutical companies, we aim to maintain the lead position in pharmacology research and drug development. At the same time, we are expanding the indication into infectious diseases (antiviral), and strive to become the leading innovator.



Focusing on the application of gene editing of a novel immune oncology target in immunotherapy, we aim to maintain the lead position in clinical applications, and strive to become a global competitor.


Medical Aesthetics

Focusing on establishing a world class medical aesthetics R&D platform and integrating innovation with marketing insight, we aim to apply our deep understanding of Chinese consumers and Chinese distribution channels to share the dividends of the social progress and consumption upgrade, and strive to become the leader in medical aesthetic in China market.


Pet Medicine

Leveraging the cutting-edge research and development achievements of biomedical research and the deep insight into pet medicine market in China, we aim to establish a strong product pipeline and launch a serial of innovative pet medicine products, and quickly establish ourselves as the leader in China pet medicine market.



Online Contract Signing Ceremony: Xi'an Yufan Biotechnology plans to invest 100 million Yuan to build a CAR-T cell manufacturing facility

On Feb 22, 2020, a contract signing ceremony of Xi 'an Biomedical Industry Cluster Group was held in Xi 'an High-tech District. To ensure the safety of participants during the pandemic, the contract signing was carried out via a special online ceremony, changing the way of contract signing from "face to face" to "screen to screen".

MingMed Biotechnology Opening Ceremony

In the afternoon of April 19, 2020, Guangzhou MingMed Biotechnology Co., Ltd. held its Opening Ceremony.



MingMed Biotechnology R&D team features world class scientists and global industry leaders. The management team is comprised of senior managers and serial entrepreneurs from pharmaceutical company, investment firm and commercial organization. The core team members have known each other for more than 20 years with long standing trust.


Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1